ImClone Systems and Bristol-Myers Squibb said Monday results of a late-stage study showed Erbitux and chemotherapy combined failed to meet their primary goal as a colon cancer treatment.
In November, the companies said cancer drug Erbitux, in combination with irinotecan, failed to extend overall survival in patients who had received previous treatment.
Source
No comments:
Post a Comment